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Why was the cohort set up?
The Nijmegen Biomedical Study (NBS) is a population-based
study that was initiated (by L.K. and A.V.) in 2000 in the mu-
nicipality of Nijmegen ( 150 000 inhabitants) in the eastern
part of The Netherlands. The NBS was originally established
to obtain a universal reference population to be used for stud-
ies of genetic variation, lifestyle and environmental exposures
in relation to traits or diseases of interest. However, NBS has
also proven useful for studying population traits. The NBS
was set up by the Department for Health Evidence, the
Department of Laboratory Medicine and the Department of
Internal Medicine of the Radboud university medical center
(Radboudumc) in Nijmegen in collaboration with the munici-
pality of Nijmegen and the community health service of
Nijmegen. At a later stage, the Department of Human
Genetics of the Radboudumc joined the NBS project team.
Approval to conduct the NBS was obtained from the
Radboud university medical center Institutional Review
Board. All participants gave written informed consent.
Who is in the cohort?
The logistic set-up of the NBS was tested in a pilot study
performed between November 2001 and February 2002.
Via the population registers of the municipality of
Nijmegen, the names and addresses of 650 males and fe-
males aged 18 years and older were obtained. They each
received a questionnaire with questions about, for ex-
ample, lifestyle and health status. Of the 650, 342 ques-
tionnaires were filled out and returned (response rate
53%). Of these 342 persons, 262 (77%) also donated a
blood sample. Execution of the pilot study led to further
optimization of the study procedure, especially in the
blood sampling procedure: the number of community of-
fices for blood donation was decreased and their opening
hours were extended.
In 2002, the first phase of NBS (NBS-1) was started. On
1 July, a random sample from the register of the municipal-
ity of Nijmegen was drawn, stratified by sex and 5-year age
groups. Eligibility criteria were age 18 years or older, not
living in an institution or rest home and the ability to fill
out a questionnaire in Dutch. In total, 22 451 inhabitants
of the municipality of Nijmegen were invited to fill out a
postal questionnaire (NBS-1 QN) and to donate an 8.5-ml
blood sample in a serum separator tube and one (for N 
5000) or two (for N  1500) 10-ml EDTA blood samples.
Of the invited participants, 96% were of Dutch nationality.
Table 1 shows the age distribution of the invited
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participants, separately for males and females. Sampling
fractions per sex and 5-year age group are available on
request.
The overall response to the questionnaire was 42% (N
¼ 9350), and 69% (N¼ 6468) of the responders donated
blood samples. Table 1 shows an overview of response
rates stratified by age and gender. The main reasons for
non-participation based on a telephone survey among 65
non-responders were ‘not interested’ (32%), and ‘age (too
old)’ (14%).
How often have they been followed up?
The first phase of NBS has been followed by four add-
itional phases across the period 2002-16 (Figure 1). There
are currently no plans to conduct additional rounds of fol-
low-up.
NBS-2 and NBS-2-NIMA
NBS-2 was initiated in 2005, with additional health-
related questions of interest to the researchers. All partici-
pants of NBS-1 who had given permission to be
approached for further research were invited to partici-
pate. Based on their age on 1 November 2005, participants
were invited for different additional methods of data col-
lection, in addition to the basic NBS-2 questionnaire (NBS-
2 QN), which was sent to all.
Age below 50 years
Of the 2926 participants who were approached to fill out
the NBS-2 QN, 1884 (64%) completed and returned the
QN.
Age between 50 and 70 years
Of the 2807 participants, 2114 (75%) filled out the NBS-2
QN. Furthermore, 1517 of the 2807 people (54%) partici-
pated in the NBS-2-NIMA1 study at the Department of
Internal Medicine; this sub-study focused on cardiovascu-
lar risk prediction using non-invasive measurements of ath-
erosclerosis (NIMA), namely intima-media thickness
(IMT), endothelium function using flow-mediated dilata-
tion (FMD), ankle-brachial index (ABI) and pulse-wave
velocity (PWV). All NIMA1 participants (N ¼ 1517) were
re-invited in 2012 to fill out an additional questionnaire;
1423 (87%) responded. In addition, 95 of 100 randomly
invited NIMA1 participants underwent repeated NIMA at
this time. Of these 95 participants, 20 were measured again
within 2 weeks to determine repeatability of the measure-
ments. Currently NBS-2-NIMA3 is being executed, with
focus on the role of intestinal bacteria in the development
of atherosclerosis. Invitations were sent to participants of
NBS-2-NIMA2 with a body mass index (BMI) > 27 kg/m2
(N ¼ 561) and to participants with a BMI > 25 kg/m2 and
< 27 kg/m2 who indicated that their weight had increased
(N ¼ 397); also, friends/family of the participants (N ¼
145) were invited. Of all invited persons, 302 participated
in this part of the study.
Table 1. Age and sex distribution of the sample taken on 1 July 2002
Males Females
Age group
(years)
N invited
(% of total)
N of QN
returned
(% of N invited)
N of blood
samples donated
(% of N invited)
N invited
(% of total)
N of QN
returned
(% of N invited)
N of blood
samples donated
(% of N invited)
18-24 828 (8%) 247 (30%) 108 (13%) 826 (7%) 425 (52%) 215 (26%)
25-29 852 (8%) 230 (27%) 117 (14%) 864 (8%) 373 (43%) 195 (23%)
30-34 881 (8%) 268 (30%) 137 (16%) 866 (8%) 408 (47%) 227 (26%)
35-39 853 (8%) 262 (31%) 152 (18%) 837 (7%) 383 (46%) 256 (31%)
40-44 833 (8%) 297 (36%) 185 (22%) 803 (7%) 372 (46%) 258 (32%)
45-49 808 (7%) 336 (42%) 216 (27%) 799 (7%) 422 (53%) 307 (38%)
50-54 801 (7%) 325 (41%) 228 (29%) 802 (7%) 402 (50%) 311 (39%)
55-59 805 (7%) 346 (43%) 269 (33%) 788 (7%) 358 (45%) 298 (38%)
60-64 819 (7%) 384 (47%) 312 (38%) 787 (7%) 409 (52%) 333 (42%)
65-69 811 (7%) 433 (53%) 348 (43%) 786 (7%) 405 (52%) 323 (41%)
70-74 778 (7%) 391 (50%) 310 (40%) 766 (7%) 344 (45%) 267 (35%)
75-79 766 (7%) 366 (48%) 299 (39%) 762 (7%) 298 (39%) 214 (28%)
80-84 755 (7%) 307 (41%) 232 (31%) 750 (9%) 225 (30%) 146 (20%)
 85 363 (3%) 115 (32%) 80 (22%) 1,062 (7%) 219 (21%) 125 (12%)
Total 10953 (100%) 4307 (39%) 2993 (27%) 11498 (100%) 5043 (44%) 3475 (30%)
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Age above 70 years
Of the 2253 participants aged above 70 years who had
given permission to be approached for further research and
were still alive, 1596 filled out the NBS-2 QN (71%).
NBS-3
In 2008-10, NBS-3 was carried out to obtain more detailed
information about the nutritional status. A total of 5363
people were invited to fill out a food frequency question-
naire (FFQ). This FFQ was a validated instrument de-
veloped by the Division of Human Nutrition at
Wageningen University.1,2 Crude questionnaire data were
converted to nutrient intake using the Dutch Food
Composition Table from 2006 (NEVO 2006); these data
are available for 2506 participants (47%).
NBS-4
In 2008 NBS-4 was started, to increase compatibility and
similarity in available (risk factor) data between the NBS
and cancer patient groups that were frequently studied by
our research group, as well as to collect trait data and
health information for a broader range of studies. A new
questionnaire (NBS-4 QN) was sent out to 8109 persons
who had given permission to be approached for further re-
search and were still alive, of whom 5613 (69%)
responded.
NBS-5
The NBS-5-phase was conducted in 2012 in order to col-
lect reference data for a study on risk factors for melanoma
and to obtain data on pain, dyslexia and more extensive in-
formation on physical activity. Of the 7567 persons who
had given permission to be approached for further research
and were still alive, 3833 (51%) returned their question-
naire (NBS-5 QN).
What has been measured?
Questionnaires
The NBS-1 QN contained questions on, among other
topics, demographics, health status, lifestyle and medical
Figure 1. Schematic overview of the data collection over time within the five NBS phases. Participants of NBS-1 were invited to participate in subse-
quent NBS phases if they had given permission to be approached for further research and were eligible for inclusion.
FFQ¼food frequency questionnaire, N¼number, NIMA¼non-invasive measurements of atherosclerosis, QN¼questionnaire, y¼year.
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history. The NBS-2 QN covered topics about health and
disease, pregnancy, mood and behaviour, daily activities
and memory. The NBS-2-NIMA1, 2, and 3 QNs contained
questions on general health, medical history (with a focus
on cardiovascular traits), use of medication, lifestyle, fam-
ily history of cardiovascular traits, and quality of life.
NBS-3 QN was a food frequency questionnaire. NBS-4
QN was about lifestyle factors and health and disease. In
addition, questions about reading problems, mood and be-
haviour, and life events were included. Finally, NBS-5 QN
focused on health and disease, sun exposure, physical ac-
tivity, pain and reading problems. A more detailed over-
view of the questionnaire data collected in the different
NBS phases is provided in Table 2.
Biomaterials and blood parameters
In NBS-1, 6468 participants donated a non-fasting 8.5-ml
blood sample in a serum separator tube (serum sample),
and one (N  5000) or two (N  1500) non-fasting 10-ml
EDTA blood samples (plasma sample). Blood samples
were taken throughout the day; time of blood sampling
was recorded. Plasma and serum samples were stored at
the Department of Laboratory Medicine at -40 C until
use. Cell pellets were frozen and also stored at -40 C for
future DNA isolation.
In NBS-2-NIMA1, fasting blood samples were obtained
for all participants: two 8.5-ml serum tubes, two 10-ml
EDTA tubes and one 10-ml heparin tube were collected. In
addition, a urine sample was collected. In NBS-2-NIMA3,
fasting blood samples were obtained again: one 10-ml
serum separator tube, two 10-ml EDTA tubes and one 10-
ml heparin tube. In addition, urine and faeces samples and
swabs from mouth, hand, foot and back for microbiome
isolation, as well as adipose tissue biopsies (from abdomen
and thigh) were collected. Haematological and biochem-
ical parameters that have been measured in the NBS blood
samples are presented in Table 3.
Genomics
Initially, genome-wide genotyping was carried out for
1980 samples using the Illumina HumanHapCNV370-
Duo BeadChip platform, of which 1819 survived quality
control (QC). Currently, we have genome-wide genotype
data measured with the Illumina HumanOmniExpress-12
and -24 BeadChip available for 5363 samples; 5292 of
these passed a call rate threshold of 95% and were imputed
using the 1000 Genomes phase1 v314 together with
Genome of The Netherlands (GoNL) release 515 data as
reference. Pre-imputation QC on the marker level con-
sisted of a minor allele frequency (MAF) > 0.01, Hardy-
Weinberg equilibrium (HWE) P-value > 10-4 and a single
nucleotide polymorphism (SNP) yield > 95%, resulting in
609 046 SNPs to be used in the imputation process.
Imputation was performed using the Impute2 pipeline de-
veloped by the GoNL team; see [http://www.bbmriwiki.nl/
wiki/Impute2Pipeline].16 This resulted in 20 011 335
SNPs. Post-imputation quality control consisted of exclu-
sion of population outliers using principal component ana-
lysis, exclusion of sex discrepancies based on a comparison
of genotype data and clinical data, and a relatedness check,
which resulted finally in 4745 samples available for
genome-wide analyses.
In addition, 1931 NBS samples have been chipped with
the Illumina HumanExome BeadChip, which covers puta-
tive functional exonic variants and is focused on the meas-
urement of rare (MAF < 0.5%) and low-frequency
(0.5%< MAF < 5%) variants [http://genome.sph.umich.
edu/wiki/Exome_Chip_Design]. A total of 242 901 vari-
ants were measured with this chip, and data were called
both in GenomeStudio and with zCall, a caller specifically
designed for calling rare variants.17 After quality control,
that is sample call rate > 95%, removal of sex discrepan-
cies, a relatedness check, a heterozygosity check, exclusion
of population outliers, marker call rate > 98%, exclusion
of markers that should be treated with caution–see Exome
Chip Design Wiki: [http://genome.sph.umich.edu/wiki/
Exome_Chip_Design]–and HWE > 10-6, a set of 1825
samples and 242 703 markers are available for association
analysis.
Linkage to the Netherlands Cancer Registry
The NBS database has been linked to the database of the
Netherlands Cancer Registry in order to obtain official
registry data on the occurrence of cancer among the NBS
participants. Linkage was executed based on identifying in-
formation such as name, date of birth and date of death.
Linkage has been repeated several times in order to update
information on the occurrence of cancer. The latest linkage
was performed in 2014, resulting in complete information
on the occurrence of cancer in the NBS participants until
2012 and partly for 2013.
Linkage with the population registers of the
municipality of Nijmegen
Periodically (in the beginning monthly, nowadays every 6
months), we receive updates from the municipality of
Nijmegen about changes in vital status or address of the
NBS participants who still live in the original catchment
area. In this way, we have an up-to-date database of the
latest contact information and vital status of the NBS
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participants. This linkage does not provide information on
causes of death, neither can we obtain these data due to a
lack of informed consent.
What has it found? Key findings and
publications
The first paper based on NBS data was published in 2006,
which was about thyroid function and presence of anti-
thyroperoxidase antibodies in the NBS.18 Up to 22 June
2016, there have been 171 peer-reviewed articles published
that used data from the NBS. An up-to-date list can be
found on our website [www.nijmegenbiomedischestudie.
nl]. The papers cover a wide range of topics, as there is a
large variety of demographic, clinical, biochemical and
genetic variables available. The project team of the NBS it-
self is focused on research into bladder cancer, atheroscler-
osis and cardiovascular risk factors, disorders of iron
metabolism and psychiatric disorders in the adult popula-
tion (like attention deficit/hyperactivity disorder (ADHD)
and autism spectrum disorders).
The NBS has contributed genetic data to many interna-
tional consortia that studied genome-wide DNA variation
in relation to binary disease phenotypes, using the NBS par-
ticipants as a control group, and quantitative traits. This
has led to the identification of novel associations between
DNA variants and a whole range of traits and diseases, for
example urinary bladder cancer,19–22 schizophrenia23 and
educational attainment.24 Furthermore, smaller-sized gen-
etic studies that zoomed in on specific candidate genes have
been performed using NBS data.25–27 Also, genetic vari-
ation has been used to draw conclusions about causality of
risk factor-outcome associations. An example is a
Mendelian randomization study that indicated that iron
traits might play a role in atherosclerosis.28
Phenotypic data from NBS have also been used in many
epidemiological studies. Reference values have been con-
structed for thyroid function,18 glomerular filtration
rate29,30 and hepcidin.31 In addition, data from the NBS-2-
NIMA sub-study have been exploited to study risk factors
and risk prediction models for atherosclerosis and cardio-
vascular traits.32–37 This revealed, for example, that waist
circumference is independently associated with subclinical
atherosclerosis.36 Finally, NBS has been used as a control
group for studies into risk factors of bladder cancer and
prostate cancer.38–40 One of these studies showed that
there is no association between personal hair dye use and
bladder cancer risk, also when taking various types of hair
dye, intensity of exposure to hair dyes or dye colour into
account.38T
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What are the main strengths and
weaknesses?
The NBS was designed to obtain a universal reference
population and it has been extremely valuable as such. A
main strength of NBS is that the participants are very well
phenotyped, with data on a wide variety of variables,
phenotypical, environmental and biochemical; NBS thus
provides a very rich source of information on a broad
range of research questions. In addition, data collection in
consecutive phases has allowed collection of information
on additional topics that were not covered in NBS-1.
Besides, the NBS database has been linked to databases of
the Netherlands Cancer Registry, increasing the amount of
data available for analysis even further. The NBS is also a
relatively large study population, containing questionnaire
data on almost 10 000 participants and genomics data for
more than 5000 participants. Finally, contact information
and vital status of the NBS participants living in the ori-
ginal catchment area have been kept up to date using infor-
mation on mutations from the register of the municipality
of Nijmegen which is sent to us on a regular basis. NBS
participants are thus approachable for future research as a
source population for new studies. For example, NBS is
currently participating in the Biobank Netherlands Internet
Collaboration (BIONIC) study [http://www.emgo.nl/re
search/cross-campus-collaborations/research-projects/
1454/bionic-biobank-netherlands-internet-collaboration-
proof-of-principle-for-major-depressive-disorder/back
ground/]: 3684 NBS participants were invited and 1510
have responded so far (41%).
All participants of the NBS were inhabitants of the mu-
nicipality of Nijmegen at the time of inclusion. Thus, the
NBS represents the population of the eastern part of The
Netherlands. How well the NBS represents the source
population and the Dutch population has not formally
been studied. It is known, however, that participants in the
NBS are relatively highly educated, based on informal
comparisons with the education level of the total Dutch
population and of case series that are being studied by the
NBS project team. In addition, it is important to realize
that the age distribution of the NBS is not representative of
the age distribution of the population of the municipality
Nijmegen, as the NBS sample was drawn from the register
of the population of the Nijmegen stratified by 5-year age
groups. In order to draw conclusions about prevalence of
diseases, the sampling fraction for each age group should
thus be taken into account. Sampling fractions are avail-
able on request.
Importantly, the NBS is a fixed cohort and not a dy-
namic population. The NBS cohort is consequently getting
older over time, and numbers of participants in NBSTa
b
le
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decrease due to death of the included subjects. In addition,
the subset of participants who contributed to later phases
of NBS, that is NBS-2 to NBS-5, represents most probably
a selected group of people, which should be taken into ac-
count when thinking about the generalizability of study
outcomes to the general population using data from later
phases of NBS.
Finally, blood samples collected in NBS-1 were taken
non-fasting and not at a fixed time point during the day.
This is important for some of the biochemical measure-
ments, such as the blood lipids and the iron parameters,
but can be taken into account by using recorded time of
blood sampling in statistical analysis.
Can I get hold of the data? Where can I find
out more?
The data of the NBS are freely available to the interna-
tional scientific community. The website [www.nijmegen
biomedischestudie.nl] contains information on the col-
lected data, including pdf documents of the questionnaires
(in Dutch) and a detailed file with all variables that are
available (in both Dutch and English). Researchers can
apply for use of the data (questionnaire data, laboratory
parameters and cancer registry linkage data) for scientific
projects by submitting a research plan to [info@nijmegen-
biomedischestudie.nl], which should contain information
on the background of the research, the research questions
to be answered, an analysis plan and the data requested.
Data requests will be evaluated by the NBS project team,
and after approval a Data Transfer Agreement (DTA) will
be made containing the conditions under which the data
will be transferred. The data will be provided free of any
costs, but may only be used to answer the research ques-
tion(s) specified in the research plan.
In October 2013, the NBS biomaterial collection was
transferred to the Radboud Biobank, an infrastructure
within the Radboud university medical center for the col-
lection, storage and management of biomaterial, and the
matching to clinical data.41 The biosamples are also avail-
able to the scientific community on a fee-for-service basis.
Requests can be made to the Radboud Biobank directly,
see [www.radboudbiobank.nl] for the application
procedure.
Profile in a nutshell
• The NBS is a large, well-phenotyped observational
population-based study that was established to ob-
tain a universal reference population that can be
used in a variety of (case-control) studies in order to
study genetic variation, lifestyle and environmental
exposures in relation to a variety of traits or
diseases.
• The first phase of NBS was started in 2002: 22 451
inhabitants of the municipality of Nijmegen were
invited, of whom 9350 filled out the questionnaire
and 6468 donated a blood sample. The age ranged
from 18 to 99 years.
• The initial phase of NBS has been followed by four
additional phases from 2005 to 2016, including add-
itional questionnaires and clinical and biochemical
measurements.
• Contact information and vital status of the NBS par-
ticipants living in the original catchment area have
been kept up to date until now, using information
from the demography register of the municipality of
Nijmegen; more than 6000 of the participants are
still approachable for future studies.
• Available data comprise a wide range of phenotypic,
environmental and biochemical variables, genome-
wide genetic information and linkage to the
Netherlands Cancer Registry. Also, biospecimens
(serum, plasma and DNA samples) can be requested.
• Data are freely available to the international scien-
tific community; send a request to
[info@nijmegenbiomedischestudie.nl]; see [www.nij
megenbiomedischestudie.nl for more information].
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